It has been suggested that deregulation of activin signaling contributes to tumor formation. Activin signaling is blocked in cancer cells due to the complex formed by Cripto-1, activin, and activin receptor type II (ActRII). In this study, the authors used a mammalian two-hybrid system to construct a drug screening model to obtain a small molecular inhibitor capable of interrupting the interaction between Cripto-1 and ActRII. They screened 300 natural components and identified alantolactone. Data suggested that alantolactone induced activin/SMAD3 signaling in human colon adenocarcinoma HCT-8 cells. The authors also found that alantolactone exhibited antiproliferative function specific to tumor cells, with almost no toxicity to normal cells at a concentration of 5 µg/mL. Furthermore, they proved that the antiproliferative function of alantolactone was activin/SMAD3 dependent. These results suggest that alantolactone performs its antitumor effect by interrupting the interaction between Cripto-1 and the activin receptor type IIA in the activin signaling pathway. Moreover, screening for inhibitors of Cripto-1/ActRII is a potentially beneficial approach to aid in discovering novel cancer treatment. (Journal of Biomolecular Screening 2011;16:525-535) 
C ancer is a common disease and a leading cause of death worldwide. Cancer treatment with current chemotherapeutic agents is far from satisfactory because of drug resistance and toxicity. Increasing insight into the genetics and molecular biology of cancer has resulted in the identification of potential molecular targets for anticancer drug discovery and development.
Activin, a member of transforming growth factor (TGF)-β superfamily, 1 exhibits pleiotropic functionality in physiological as well as pathological processes. One remarkable function of activin is its growth-inhibitory effect. 2, 3 The signal transduction pathway leading to the growth inhibition has been well studied at the molecular level. Activin binds to two types of serine/ threonine kinase receptors, termed type I and type II receptors. 4, 5 Type I and II receptors are able to form high-affinity receptor complexes necessary for signal transduction at the cell surface. 1 The type II receptor phosphorylates the type I receptor, which in turn propagates the signal downstream by phosphorylation of SMAD2 and SMAD3. SMADs form a complex and translocate to the nucleus to regulate the expression of specific genes, such as p21 and c-Myc. [1] [2] [3] 5 Activin is considered a tumor suppressor, and recent research indicates that a disorder of activin signaling is an initiator of tumorigenesis. 2, 4 One of the activin signaling antagonists is Cripto-1, a founding member of the EGF-CFC protein family highly correlated with tumorigenicity. 6 Cripto-1 is expressed at a high level in 75% to 80% of human colon, breast, and lung cancers, as well as 50% to 60% of testicular, stomach, pancreatic, and ovarian cancers, but is expressed at a low level in normal tissue. [7] [8] [9] [10] Previous research has demonstrated that Cripto-1 overexpressing cells exhibit increasing proliferation and excessively activated signaling pathways for cell growth in vitro. [11] [12] [13] [14] It has been reported that Cripto-1 is a modulator of TGF-β family member signaling pathways. 11, [15] [16] [17] In activin signaling transduction, Cripto-1 interacts with activin in the presence of activin receptor type II (ActRII) to form an activin-Cripto-ActRII triplex. The complex prevents the phosphorylation of ALK4 (ActRI) by ActRII and terminates subsequent downstream signaling. 4, 7, 16, 18 An activin growth-inhibitory effect is abolished because of the interruption of its signaling pathway in certain types of cancer cells. 19, 20 In this study, we used a mammalian two-hybrid system model to screen small molecular inhibitors capable of interrupting the interaction between Cripto-1 and activin receptor IIA. By screening 300 natural components extracted from plants and animals, we identified the small molecular compound alantolactone. Our data demonstrated that alantolactone could activate activin/SMAD3 signaling and thus alter the expression level of activin target genes in human colon adenocarcinoma HCT-8 cells. In addition, we demonstrated that alantolactone-activated activin signaling is the key mechanism of the antiproliferative function of alantolactone.
MAterIALS And MethodS

DNA constructs
pCI-neo-Cripto-1 was obtained from Dr. David Salomon (National Institutes of Health, Bethesda, MD). To make pcDNAc-Myc-ActRIIA, human ActRIIA cDNA, including coding regions, was cloned into a pcDNA3 vector and incorporated 7 Myc epitopes following the arginine residue (amino acid number 24). To make pcDNA-SMAD3, the entire open reading frame sequence of SMAD3 was cloned into a pcDNA3 vector. In a mammalian two-hybrid assay, the pBind vector contained the yeast GAL4 DNA binding domain upstream of a multiple cloning region, and the pAct vector contained the herpes simplex virus VP16 activation domain upstream of a multiple cloning region. The N-truncation (signal peptide-deleted) cDNA sequence and a 543-bp DNA fragment (extracellular domain) of human activin receptor type IIA (ActRIIA) were cloned into the pBind vector, respectively. The N-truncation (signal peptidedeleted) human Cripto-1 cDNA was cloned into the pAct vector. The pGAL4 and pVP16 fusion constructs were transfected along with the pG5luc vector. The pG5luc vector contained five GAL4 binding sites upstream of the minimal TATA box upstream of the firefly luciferase. To conduct the activin-responsive luciferase reporter assay, we prepared the CAGA-lux (pGL3-promoter vector) that contained three copies of the consensus SMAD2/ SMAD3 binding site upstream of the firefly luciferase reporter gene in our laboratory. To create the SMAD3 shRNA expression vector, the pRNAT-U6.1/Hygro vector (GenScript Corporation, Piscataway, NJ) was used for DNA vector-based shRNA synthesis. The pRNAT-U6.1/Hygro expressed hairpin sequences that used the U6 RNA pol III promoter. For each target, the sense and antisense strands were separated by a loop that comprised nine nucleotides (5′-TTCAAGAGA-3′) and a polythymidine tract to terminate transcription. The short-interfering RNA (shRNA) targeting SMAD3 sequences were designed and synthesized as described previously. 21 A negative control scrambled shRNA (GenScript Corporation) GACGCTTACCGATTCAGAA with no significant homology to mouse or human gene sequences was designed to detect any nonspecific effect.
Antibodies and reagents
Polyclonal antibody against Cripto-1 was prepared by our lab. Antibodies against SMAD2/3 and c-Myc were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against p-SMAD3 and p21 were purchased from Cell Signaling Technology (Beverly, MA). Cy3-conjugated secondary antibody was obtained from Beyotime (Shanghai, China). Peroxidaseconjugated goat anti-mouse IgG (H+L) and peroxidase-conjugated goat anti-rabbit IgG (H+L) were obtained from Jackson ImmunoResearch (West Grove, PA). DAPI (4, 6-diamidino-2phenylindole) was purchased from Beyotime.
The chemical compounds were purchased from National Institute for the Control of the Pharmaceutical and Biological Products (NICPBP, Beijing, China). The purity of the compounds was ≥98%.
Cell lines and cell culture
Human normal liver cells (L02), human colorectal adenocarcinoma cells (HCT-8), and human embryonic kidney 293 T cells (HEK 293 T) were maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO) supplemented with 10% fetal bovine serum (FBS; [v/v]; Sijiqing Biological Engineering, Hangzhou, China), 100 U/mL penicillin, and 100 mg/mL streptomycin (Ameresco, Solon, OH) and penicillin and incubated at 5% CO 2 in a 37 °C incubator.
To develop the Cripto-1 stable expression cell line (L02-Cripto-1), L02 cells were grown at a 60% to 70% confluence and transfected with Cripto-1 expression vectors (Lipofectamine 2000; Invitrogen, Carlsbad, CA). A final concentration of 500 µg/mL G418 was used as the optimal concentration of drug for selection. Western blot was used to assess the Cripto-1 expression levels of L02-Cripto-1 and L02-neo cells.
Immunoprecipitation
HEK 293T cells were cotransfected with Cripto-1 and c-Myc-ActRIIA expression plasmids using a Calcium Phosphate Transfection Kit (Beyotime) according to the manufacturer's protocol. After 48 h, transfected cells were harvested and lysed in immunoprecipitation lysis buffer (Roche Diagnostics, Indianapolis, IN) for 30 min at 4 °C. Lysates were clarified by centrifuging at 12 000 g for 5 min, and then the supernatant fraction was used for immunoprecipitation.
The lysates were cleared with 10 µL protein A/G-plus agarose beads for 1 h at 4 °C. The c-Myc-ActRIIA protein was immunoprecipitated from whole-cell lysates using antibody against c-Myc tag. After a 3-h incubation, protein A/G-plus agarose beads were added (10 µL; Roche Diagnostics), and incubation was continued for 3 h at 4 °C. Immunoprecipitates were washed with lysis buffer (Roche Diagnostics) and subsequently subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on 12% gels (w/v) followed by Western blot using antibody against Cripto-1.
Mammalian two-hybrid and luciferase reporter assay
For the mammalian two-hybrid assay, pAct-Cripto-1, pG5luc, and pBind-ActRIIA or pBind-EXActRIIA plasmids were cotransfected into HEK 293T cells using a Calcium Phosphate Transfection Kit (Beyotime) according to the manufacturer's recommended protocol. Briefly, HEK 293T cells were grown at 60% to 70% confluence and cultured for 24 h. Total plasmids (1 µg/well) were transfected and cultured for 24 to 48 h prior to the luciferase reporter assay.
Regarding the activin-responsive promoter assay, HCT-8 cells were seeded in a 24-well plate, then transfected with 1 µg reporter plasmid per well plus 0.1 µg of pCMV-β-galactosidase plasmid to normalize transfection efficiency. After 36 h, cells were incubated in 500 µL serum-deprived medium in the presence of 10 ng activin A or 2 µg/mL alantolactone for 4 h before luciferase reporter assay.
To conduct the luciferase reporter, assay cells were harvested and washed twice with phosphate-buffered saline (PBS), then lysed in 85 µL cold lysis buffer ( were added to 45 µL cell lysate. Luciferase activity was then measured using a FLUOstar OPTIMA fluorescence reader (BMG LABTECH, Offenburg, Germany). β-Galactosidase activity was measured using a β-galactosidase assay system (Promega Biosciences, San Luis Obispo, CA).
Chemical compounds screening
Chemical compounds extracted from plants and animals were dissolved in DMSO as a 10-mg/mL stock. The assay was dependent on detection of the level of luciferase, which was expressed by a pG5luc reporter plasmid. HEK 293T cells were grown to 60% to 70% confluence, then transfected with pBind-EXActRIIA, pAct-Cripto-1, and pG5luc plasmid (5 µg in total). Twenty-four hours later, reasonable quantities of transfected cells were equally distributed into 96-well plates and incubated for another 12 h, at which point the medium changed to DMEM containing 3% FBS (v/v) and candidate chemical compounds (5 µg/mL). The luciferase assay was performed 4 to 8 h after drug treatment, and 0.1% DMSO (w/v) was used as the negative control.
Protein extraction and Western blot
Cells were treated as indicated, followed by resuspension in cell lysis buffer (1% Triton X-100, 0.015 M NaCl, 10 mM Tris-HCl, 1 mM EDTA, 1 mM phenylmethanesulfonylfluoride [PMSF], 10 µg/mL each of leupeptin and pepstain A) and then incubated on ice for 30 min. The cell lysates were centrifuged at 12 000 g for 5 min at 4 °C, and the supernatants were mixed with one-quarter volume of 4× SDS sample buffer, boiled for 5 min, and then separated through a 12% (w/v) SDS-PAGE gel. After electrophoresis, proteins were transferred to PVDF membranes and blocked with 5% (w/v) nonfat dry milk in TBST buffer (20 mM Tris-HCl [pH 7.6], 150 mM NaCl, and 0.05% Tween-20) for 1 h at room temperature. The membranes were probed with diluted primary antibodies in 1% (w/v) milk/TBST for 24 h at 4 °C, washed three times, incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 30 min at room temperature, and washed extensively before detection by chemiluminescence with the ECL-Plus kit (Beyotime). Protein bands were visualized by exposing the blots to Kodak film.
Immunofluorescence
For immunofluorescence analysis, 1.5 × 10 5 cells were seeded in a 24-well plate. Twenty-four hours later, cells were incubated in 500 µL serum-deprived medium in the presence of 10 ng activin A or 2 µg/mL alantolactone for 2 h. Samples were formalized with 4% (w/v) paraformaldehyde for 15 min and permeabilized with 0.5% (v/v) Triton X-100 for 10 min. Immunofluorescence staining was performed using anti-SMAD2/3 polyclonal antibody overnight at 4 °C and with Cy3-conjugated secondary antibody. Samples were examined using a fluorescence microscope with appropriate filters. Nuclei were stained with DAPI.
RNA interference experiments
HCT-8 cells were grown to 70% to 80% confluence and transfected with double-stranded siRNA for SMAD3 using Genetran II Transfection reagent (Biomiga, San Diego, CA). After transfection, cells were incubated for another 48 h, and silencing efficiency was confirmed by Western blot.
Cell viability analysis
The colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay was performed to quantify the effect of alantolactone on cell viability.
HCT-8 cells were plated in 96-well plates (5000 cells/well) in 100 µL of growth medium and allowed to grow for 24 h, at which time the medium was changed to DMEM containing 3% (v/v) FBS and 5 µg/mL alantolactone. The assay was performed after 24 and 48 h, respectively. Then, 20 µL MTT solution (5 mg/mL in PBS) was added to each well, and the plates were incubated for 4 h until purple precipitate was visible. Next, 50 µL of DMSO was added to each well and agitated for 10 min to dissolve the formazan crystals. Absorbance in each well was read at 570 nm by an Automated Microplate Reader (Bio-Rad, Hercules, CA).
For 6 days cell-growth curve description, HCT-8 cells were seeded in a 6-well plate at 60% to 70% confluence and transfected with indicated vectors. After 36 h, transfected cells in each well were harvested and reseeded in 96-well plates (1000 cells/well) and allowed to grow for 24 h, at which time the medium changed to DMEM containing 3% (v/v) FBS and 2 µg/ mL alantolactone. Cells were continuously cultured for 6 days. Each day, the MTT assay described above was used to determine the cell growth level.
For cell-counting experiments, cells were seeded in a 24-well plate, incubated overnight, and then transfected with vectors as described. Twenty-four hours later, 1 × 10 4 cells per well were transferred to a 6-well plate. After cells attached, the medium was changed to DMEM containing 3% (v/v) FBS with alantolactone 2 µg/mL, and cells were continuously incubated for 6 days. Cells were then digested by 0.25% (w/v) trypsogen to produce a cell suspension, and when counting experiment was performed. viable cells per milliliter were counted using trypan blue.
Colony formation assay
HCT-8 cells were trypsinized to a single-cell suspension, seeded in a 6-well plate (1000 cells per well), and incubated in DMEM with 10% (v/v) FBS for 48 h. Then cells were treated for 10 days with alantolactone at two concentrations (0.5 and 1 µg/mL). At the end of the incubation period, cells were formalized with 4% paraformaldehyde and stained with hematoxylin and eosin (H&E).
Statistical analysis
Statistical analysis of the data was performed using the Student's t-test, and p < 0.05 was considered statistically significant.
reSuLtS
Construction of drug screening model targeting ActRIIA/ Cripto-1 interaction
To obtain a molecule that could antagonize Cripto's activin signaling blocking function, we examined a previous study in which Cripto-1 formed an inactive complex with ActRII and activin. The c-Myc-tagged ActRIIA and Cripto-1 expression vectors were cotransfected into HEK-293T cells. The coimmunoprecipitation results demonstrated that in the presence of endogenous activin, Cripto-1 could be coimmunoprecipitated by activin receptor type IIA, whereas nothing was detected for the negative control ( Fig. 1A) . To further elucidate the interactions and relationships of this inactive complex, we used a mammalian two-hybrid assay in which two interactive proteins produced by separate plasmids inside the cytoplasm result in increased transcription of the reporter gene on the pG5luc vector. Because Cripto-1 binding to activin has been reported in a previous study, 4 we determined whether an interactive relationship existed between Cripto-1 and activin receptor IIA. As shown in Figure 1B , the interaction between full-length ActRIIA and Cripto-1 was detected. To our surprise, we found that there was a much stronger interaction between the extracellular domain of ActRIIA and Cripto-1 in the absence of activin; this finding has not been previously reported to our knowledge (Fig. 1B) . We regarded the novel interaction relationship as the drug target and used a mammalian two-hybrid assay to construct the drug screening model targeting the protein-protein interaction.
Drug screening for extracellular domain of ActRIIA/ Cripto-1 interaction inhibitor
To obtain a chemical compound that could interrupt the interaction between Cripto-1 and extracellular domain of ActRIIA, 300 candidate chemical compounds were screened by a mammalian two-hybrid drug screening model. The effect of drugs on the ActRIIA/Cripto-1 interaction was measured by detection of the luciferase level. The results found in table 1 show the percentage of interaction inhibition regarding drug treatment. Alantolactone was particularly effective concerning the interruption effect in the drug screening mode. The interaction inhibition was more than 50% compared to the negative control.
Identification of alantolactone as an inhibitor of ActRIIA/ Cripto-1 interaction
The molecular structure of alantolactone, a MeOH extract of the root of Inula helenium, is shown in Figure 2A . To confirm the results of the primary drug screening, we repeated a mammalian two-hybrid assay in triplicate, and each time alantolactone decreased the luciferase level more than 50% as compared to the negative control (Fig. 2B) . In addition, we reconfirmed alantolactone's interruption activity by performing a coimmunoprecipitation assay. ActRIIA and Cripto-1 overexpressing cells were treated with 1 µg/mL alantolactone for 4 h. Results indicated that alantolactone decreased the amount of Cripto-1 that could be immunoprecipitated by ActRIIA (Fig. 2c) . Figure 2d is the quantitation of Figure 2c , in which the amount of immunoprecipitated Cripto-1 decreased about 50% as compared to the negative control.
Alantolactone activates the activin signaling pathway in colon adenocarcinoma cell line HCT-8
It has been suggested that the activin signal is blocked in Cripto-1-positive cancer cells, leading to uncontrolled cell proliferation. 22 We have demonstrated that alantolactone is an inhibitor of the ActRIIA/Cripto-1 interaction. Whether alantolactone could activate the activin signaling pathway in a cancer cell line has remained unclear. To investigate this, we used the colon adenocarcinoma cell line HCT-8, in which Cripto-1 is expressed at a high level (Fig. 3A) . The activin-responsive luciferase reporter vector was used to measure the activin signaling. As shown in Figure 3B , treatment with activin A significantly increased the luciferase activity compared to 0.1% (v/v) DMSO, and alantolactone treatment also led to a similar result. In addition, we investigated whether alantolactone was a potential activin signaling activator in a concentration-dependent manner. HCT-8 cells were transfected with an activin-responsive luciferase reporter vector and incubated with an increased dose of alantolactone. Indeed, we found that activin signaling was induced by alantolactone in a concentrationdependent manner (Fig. 3c) . We next investigated the phosphorylation and nucleus translocation of SMAD3. As shown in Figure  3d , when cells were treated with 2 µg/mL alantolactone for 1.5 h, the SMAD3 phosphorylation level increased in a time-dependent manner. In addition, the immunofluorescence staining in Figure  3e demonstrates that nuclear SMAD3 accumulated after alantolactone treatment for 2 h. These results indicate that alantolactone induced activin signaling by promoting phosphorylation and nuclear translocation of SMAD3.
Alantolactone alters the expression of the target genes of activin signaling
We further examined the expression of p21, one of the target genes upregulated by SMADs at the transcription level. As shown in Figure 4A ,B, the p21 protein level was increased more than 10-fold over the control 5 h after incubation with 2 µg/mL alantolactone. In addition, we analyzed c-Myc (Fig.  4c,d) , another target gene negatively regulated by activin signaling. 21 After alantolactone treatment for 1.5 h, the expression level of c-Myc decreased to approximately 6-fold over the control. These results confirmed that alantolactone could activate the activin signaling pathway in HCT-8 cells.
Alantolactone inhibits cell proliferation in colon adenocarcinoma HCT-8 cells
P21 was upregulated in the HCT-8 cell line by alantolactone treatment, potentially leading to an inhibition of proliferation of cancer cells. A previous study has shown that alantolactone displayed in vitro cytotoxicity against cancer cell lines. 23 We investigated whether alantolactone inhibited the proliferation activity in the HCT-8 cell line. As shown in Figure 5A , the normal human liver cell line L02 was used to determine the nontoxic dose of alantolactone. Compared with L02 cells, alantolactone displayed an obvious superiority on HCT-8 cell growth inhibition at a final concentration of 5 µg/mL. Furthermore, we used a 48-h growth curve to investigate the effect of alantolactone on the proliferation of HCT-8 cells. As shown in Figure 5B , upon 24-h treatment, the viability of the cells was slightly decreased compared with cells treated by 
Activation of activin signal is necessary for the antitumor effect of alantolactone
Because it was demonstrated that Cripto-1 had growth stimulatory properties, we investigated whether the activated activin signaling was generated from the interrupted activity of alantolactone or from the downregulation of Cripto-1. 13, 14 Figure 6A shows that alantolactone treatment could not significantly change the level of Cripto-1. Alantolactone was evaluated for in vitro cytotoxicity against the cancer cell lines of the colon, ovary, prostate, lung, central nervous system, and in leukemia. 23, 24 Activin signaling appeared to suppress the cell proliferation. We investigated whether the antiproliferative function of alantolactone occurred in an activin/SMAD-dependent manner. SMAD3 was either overexpressed or knocked down in HCT-8 cells, as determined by Western blot (Fig. 6B) . Next, the proliferation capability of these cells was evaluated by a cell-counting experiment. As shown in Figure 6c , 6 days after transfection, the number of viable HCT-8 cells transfected with the SMAD3 expression vector was less than the control. On the contrary, knockdown of SMAD3 increased the viability of HCT-8 cells. Alantolactone-treated HCT-8 cells transfected with the SMAD3 expression vector displayed 40% decreased cell viability as compared to the pc-DNA control. For SMAD3 knockdown of HCT-8 cells, there was more than a 50% increase in antigrowth activity of alantolaction compared with the pRNAT group, suggesting that the SMAD3 knocked-down cells were less sensitive to alantolactone treatment. To confirm this finding, a growth curve was used to measure the evolution of cell viability over time. The growth rate of cells in each transfection group was measured by the MTT assay, as shown in Figure 6d . Various HCT-8 cell growth curves appeared linear from day 1 to day 6. It was demonstrated that the SMAD3 knockdown significantly enhanced the growth rate of HCT-8 cells in 6 days. In addition, upon 72 h of alantolactone treatment, SMAD3 knockdown cells displayed a nearly 50% increased cell viability compared with the control groups (cells transfected with pRNAT vector) but 30% lower viability than the groups incubated with DMSO. On the contrary, SMAD3 overexpressed cells exhibited a lower growth rate in 6 days compared with the pcDNA control cells. Furthermore, SMAD3 overexpression enhanced the sensitivity of HCT-8 cells to alantolactone. After 6 days of incubation with alantolactone, SMAD3-overexpressed HCT-8 cells exhibited a continually suppressed growth rate compared with the control groups. These observations suggest that the antitumor effect of alantolactone in HCT-8 cells was at least partially dependent on activin signaling.
dIScuSSIon
In vitro drug screening aiming to identify highly effective anticancer therapeutic agents that carry fewer negative side effects has been an area of active research in the past decade. Several drug candidates have exhibited positive anticancer activity, but the mechanism remains unclear. 25 In our study, protein-protein interactions occurring specifically in cancer cells were selected as the molecular targets. We used a mammalian two-hybrid assay to imitate the protein interaction to construct a drug screening model in HEK293T cells.
A previous study demonstrated that Cripto-1 blocked activin signaling by forming a complex with activin and activin receptor type II (ActRII), 4, 17, 18 and a new interaction between Cripto-1 and the extracellular domain of ActRII was identified. Using the mammalian two-hybrid assay, we determined that there was a strong interaction between Cripto-1 and the extracellular domain of ActRII that had not yet been reported. Because alteration in activin signaling has been demonstrated to be an important early step in tumorigenesis, 2, 16 we established a novel interaction system to determine specific targets to screen chemical compounds with antitumor activity. After 300 chemical compounds were screened under identical conditions, alantolactone was found to disrupt the interaction between Cripto-1 and the extracellular domain of ActRIIA. At this point, it was unclear which molecular target bound alantolactone and whether this interruption was direct.
Active compounds were required to be effective and also minimally cytotoxic. Alantolactone has been reported as a nonspecific alkylating agent. 26 In our investigation, we did not find alantolactone to have a significant effect on normal cells. Compared to the human normal liver cell line L02, alantolactone exhibited significant proliferative inhibition activity on the HCT-8 cancer cell line, suggesting that alantolactone could be a potential drug for colon cancer treatment.
It has been demonstrated that blocking of activin signaling is one of the mechanisms through which Cripto-1 promotes tumorigenesis. 2, 4, 17 Human colon adenocarcinoma HCT-8 cells expressing a high level of endogenous Cripto-1 were used to investigate the effect of alantolactone on the activin signaling pathway. In our study, both the luciferase reporter assay and Western blot showed that alantolactone could induce activin signaling and activin target gene expression, confirming that alantolactone activated the activin signaling pathway in a cancer cell line. Furthermore, we focused on the alteration downstream of the activin receptor. Because SMADs are the direct transducers downstream of the activin receptor, 5, 27 alantolactone should promote SMAD2/3 nuclear translocation in a very short time. As shown in Figure 3d , nuclear SMAD2/3 accumulated in 2 h after alantolactone treatment. Taken together, the results above indicate that the activin signal transducer SMAD3 might be responsible for the activity of alantolactone. Using our screening model, we found that alantolactone induced activin signaling by interrupting the interaction between Cripto-1 and the extracellular domain of ActRIIA, without having a significant impact on the binding relationship between activin and activin receptors, indicating that alantolactone might revive activin signaling and cause inhibition of cell growth in cancer cells. However, activin belongs to the TGF-β family, and some of the signaling transductants activated by alantolactone treatment are shared; both activated TGF-β and activin signaling affect cell growth inhibition.
Our further study suggested that the antiproliferative function of alantolactone occurred through activated activin signaling. The downstream conductor of an activin receptor, SMAD3, was demonstrated to play a key role in the alantolactoneinduced antigrowth function. When SMAD3 was knocked down, the antigrowth effect of alantolactone was partly minimized. However, we did not demonstrate whether alantolactone could affect the expression level of other growth factors, which potentially also contributes to antigrowth activity.
Cripto-1 plays an important role in stem cell differentiation and embryonic development. 28 It has recently been reported that a Cripto-1-specific blocking tool has been developed that could mimic the deletion of Cripto-1 and reduce tumor formation. 29 In our study, alantolactone is also considered an antagonizing agent of Cripto-1 in vitro, but the safety of potential therapeutics remains to be further investigated. Also, the effect of alantolactone in vivo needs to be addressed. Above all, use of a drug screening model to identify active chemical compounds with a high efficiency and a low toxicity is a promising method for discovering new drug candidates. Here, alantolactone was identified from 300 chemical compounds using a mammalian two-hybrid system as a screening model, which could inhibit proliferation of HCT-8 cells. The antigrowth function of alantolactone was attributed to the interruption of interaction between ActRIIA and Cripto-1, leading to activation of the activin signaling pathway. Alantolactone is a novel and potent activin signaling activator able to inhibit colon cancer cell proliferation.
